Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Retained Earnings (2022 - 2026)

Lexeo Therapeutics' Retained Earnings history spans 2 years, with the latest figure at -$181.8 million for Q4 2023.

  • On a quarterly basis, Retained Earnings fell 57.51% to -$181.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$181.8 million, a 57.51% decrease, with the full-year FY2023 number at -$181.8 million, down 57.51% from a year prior.
  • Retained Earnings hit -$181.8 million in Q4 2023 for Lexeo Therapeutics, down from -$167.7 million in the prior quarter.
  • Over the last five years, Retained Earnings for LXEO hit a ceiling of -$115.4 million in Q4 2022 and a floor of -$181.8 million in Q4 2023.